Halofuginone suppresses the lung metastasis of chemically induced hepatocellular carcinoma in rats through MMP inhibition

Bosch, 2004, Primary liver cancer: worldwide incidence and trends, Gastroenterology, 127, S5, 10.1053/j.gastro.2004.09.011 Bruix, 2004, Focus on hepatocellular carcinoma, Cancer Cell, 5, 215, 10.1016/S1535-6108(04)00058-3 Shiina, 2005, A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma, Gastroenterology, 129, 122, 10.1053/j.gastro.2005.04.009 Granot, 1991, Increased skin tearing in broilers and reduced collagen synthesis in skin in vivo and in vitro in response to the coccidiostat halofuginone, Poult Sci, 70, 1559, 10.3382/ps.0701559 Bruck, 2001, Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats, Hepatology, 33, 379, 10.1053/jhep.2001.21408 Pines, 1997, Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine-induced liver cirrhosis, J Hepatol, 27, 391, 10.1016/S0168-8278(97)80186-9 Levi-Schaffer, 1996, Inhibition of collagen synthesis and changes in skin morphology in murine graft-versus-host disease and tight skin mice: effect of halofuginone, J Invest Dermatol, 106, 84, 10.1111/1523-1747.ep12328014 Nagler, 1996, Reduction in pulmonary fibrosis in vivo by halofuginone, Am J Respir Crit Care Med, 154, 1082, 10.1164/ajrccm.154.4.8887611 Elkin, 1999, Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone, Cancer Res, 59, 4111 Gross, 2003, Treatment with halofuginone results in marked growth inhibition of a von Hippel-Lindau pheochromocytoma in vivo, Clin Cancer Res, 9, 3788 Gavish, 2002, Growth inhibition of prostate cancer xenografts by halofuginone, Prostate, 51, 73, 10.1002/pros.10059 Abramovitch, 2004, Halofuginone inhibits angiogenesis and growth in implanted metastatic rat brain tumor model-an MRI study, Neoplasia, 6, 480, 10.1593/neo.03520 Pinthus, 2005, Inhibition of Wilms tumor xenograft progression by halofuginone is accompanied by activation of WT-1 gene expression, J Urol, 174, 1527, 10.1097/01.ju.0000179218.16587.d2 Elkin, 2000, Halofuginone: a potent inhibitor of critical steps in angiogenesis progression, FASEB J, 14, 2477, 10.1096/fj.00-0292com Elkin, 1999, Inhibition of matrix metalloproteinase-2 expression and bladder carcinoma metastasis by halofuginone, Clin Cancer Res, 5, 1982 Nagler, 2004, Suppression of hepatocellular carcinoma growth in mice by the alkaloid coccidiostat halofuginone, Eur J Cancer, 40, 1397, 10.1016/j.ejca.2003.11.036 Futakuchi, 1999, Establishment of an in vivo highly metastatic rat hepatocellular carcinoma model, Jpn J Cancer Res, 90, 1196, 10.1111/j.1349-7006.1999.tb00695.x Clouzeau-Girard, 2006, Effects of bile acids on biliary epithelial cell proliferation and portal fibroblast activation using rat liver slices, Lab Invest, 86, 275, 10.1038/labinvest.3700386 Musso, 1997, In situ detection of matrix metal lop rote inase-2 (MMP2) and the metal loproteinase inhibitor TIM P2 transcripts in human primary hepatocellular carcinoma and in liver metastasis, J Hepaooogy, 593, 10.1016/S0168-8278(97)80425-4 Bieche, 2000, Quantitation of hTERT gene expression in sporadic breast tumors with a real-time reverse transcription-polymerase chain reaction assay, Clin Cancer Res, 6, 452 Butler, 1998, The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concen tration and efficient activation of progelatinase A, A kinetic study. J Biol Chem, 273, 871 Kinoshita, 1998, TIMP-2 promotes activation of progelatinase A by membranetype 1 matrix metal loproteinase immobilized on agarose beads, J Biol Chem, 273, 16098, 10.1074/jbc.273.26.16098 Egeblad, 2002, New functions for the matrix metalloproteinases in cancer progression, Nat Rev Cancer, 2, 161, 10.1038/nrc745 Itoh, 1998, Reduced angiogenesis and tumor progression in gelatinase Adeficient mice, Cancer Res, 58, 1048 Itoh, 1999, Experimental metastasis is suppressed in MMP-9deficient mice, Clin Exp Metastasis, 17, 177, 10.1023/A:1006603723759 Kruger, 2005, Antimetastatic activity of a novel mechanismbased gelatinase inhibitor, CancerRes, 65, 3523, 10.1158/0008-5472.CAN-04-3570 Theret, 2001, Increased extracellular matrix remodeling is associated with tumor progression in human hepatocellular carcinomas, Hepatology, 34, 82, 10.1053/jhep.2001.25758 Pines, 2003, Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma, Biol Blood Marrow Transplant, 9, 417, 10.1016/S1083-8791(03)00151-4 Nativ, 2004, Safety and tolerability of oral halofuginone hydrobromide in refractory recurrent transitional cell carcinoma of the bladder, J Clin Oncol, 22, 4757, 10.1200/jco.2004.22.14_suppl.4757